comprehensive -WSS

comprehensive

author：fashion 2025-09-29 21:27:16 - browse：37212

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Radiology is caught between AI's potential and concern for patients

WSS

STAT Executive Editor Rick Berke on STAT's 8th birthday

SCOTUS to consider access to abortion pill mifepristone

Roche to buy Carmot Therapeutics, developer of obesity drugs

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Abortion clinic in Cancun will cater to Americans

Patients' immediate access to test results puts radiologists in a bind

focus

comprehensive

explore

Medical leaders decry Supreme Court decision on affirmative action

Spinal cord stimulation reduces pain in amputees, study finds

As demand for Covid shots wanes, Moderna seeks its next success

Pfizer plans to depart BIO

Medicare proposal to cover medical devices draws a mixed reaction

FDA approves potent Eli Lilly obesity drug, Zepbound

Medical leaders decry Supreme Court decision on affirmative action

Senate panel clears PBM, hopsital reforms

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What causes an itch? Researchers may have solved the mystery

focus

Roche to buy Carmot Therapeutics, developer of obesity drugs

Removing probiotics from the NICU could threaten preemies' health

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

After sickle

Extreme heat events are a public health emergency

focus

focus

knowledge

leisure time